Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells

Journal of Proteomics

Volumn 75, Issue 4, 2012, Pages 1170-1180

  Shui, Hao Ai ^a   Hsia, Ching Wu ^a   Chen, Han Min ^b   Chang, Tien Chun ^c   Wang, Chih Yuan ^c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

2 D electrophoresis; Differentiation; Flotillin 1; Lovastatin; Overexpression; Proteomics

Indexed keywords

FLOTILLIN 1; MEVINOLIN;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; DRUG MECHANISM; ENZYME INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; SIGNAL TRANSDUCTION; STRUCTURAL BIOINFORMATICS; STRUCTURAL PROTEOMICS;

BLOTTING, WESTERN; CLONING, MOLECULAR; COMPUTATIONAL BIOLOGY; DNA FRAGMENTATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MEMBRANE PROTEINS; PROTEIN FOLDING; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; THYROID NEOPLASMS;

EID: 84855905371     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.10.029     Document Type: Article

References (43)

1. Pettersson F., Miller W.H., Nervi C., Gronemeyer H.J., Licht J., Tallman M.S., et al. The 12th international conference on differentiation therapy: targeting the aberrant growth, differentiation and cell death programs of cancer cells. Cell Death Differ 2011, 18:1231-1233.
2. Dimitroulakos J., Thai S., Wasfy G.H., Hedley D.W., Minden M.D., Penn L.Z. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias. Leuk Lymphoma 2000, 40:167-178.
3. Arnold D.E., Gagne C., Niknejad N., McBurney M.W., Dimitroulakos J. Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP. Mol Cell Biochem 2010, 345:1-11.
4. Wang C.Y., Zhong W.B., Chang T.C., Lai S.M., Tsai Y.F. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003, 88:3021-3026.
5. Schmidt F., Groscurth P., Kermer M., Dichgans J., Weller M. Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells. Acta Neuropathol 2001, 101:217-224.
6. Klawitter J., Shokati T., Moll V., Christians U. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. Breast Cancer Res 2010, 12:R16.
7. Moyad M.A., Merrick G.S., Butler W.M., Wallner K.E., Galbreath R.W., Kurko B., et al. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 2005, 66:1150-1154.
8. Poynter J.N., Gruber S.B., Higgins P.D., Almog R., Bonner J.D., Rennert H.S., et al. Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
9. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
10. Agarwal B., Rao C.V., Bhendwal S., Ramey W.R., Shirin H., Reddy B.S., et al. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999, 117:838-847.
11. Zhong W.B., Liang Y.C., Wang C.Y., Chang T.C., Lee W.S. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 2005, 12:615-629.
12. Zhong W.B., Wang C.Y., Chang T.C., Lee W.S. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 2003, 144:3852-3859.
13. D'Alessandro A., Zolla L. Pharmacoproteomics: a chess game on a protein field. Drug Discov Today 2010, 15:1015-1023.
14. Steiner S., Gatlin C.L., Lennon J.J., McGrath A.M., Aponte A.M., Makusky A.J., et al. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver. Electrophoresis 2000, 21:2129-2137.
15. Huang T.H., Ka S.M., Hsu Y.J., Shui H.A., Tang B.L., Hu K.Y., et al. Rab23 plays a role in the pathophysiology of mesangial cells-a proteomic analysis. Proteomics 2011, 11:380-394.
16. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 1993, 91:179-184.
17. Ramagli L. Quantifying protein in 2-D PAGE solubilization buffer. 2-D Proteome analysis protocols 1999, 99-103. Humana Press, Totowa, NJ. A.J. Link (Ed.).
18. Jensen L.J., Kuhn M., Stark M., Chaffron S., Creevey C., Muller J., et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:D412-D416.
19. Liu J., Deyoung S.M., Zhang M., Dold L.H., Saltiel A.R. The stomatin/prohibitin/flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. J Biol Chem 2005, 280:16125-16134.
20. Langhorst M.F., Reuter A., Stuermer C.A. Scaffolding microdomains and beyond: the function of reggie/flotillin proteins. Cell Mol Life Sci 2005, 62:2228-2240.
21. Munderloh C., Solis G.P., Bodrikov V., Jaeger F.A., Wiechers M., Malaga-Trillo E., et al. Reggies/flotillins regulate retinal axon regeneration in the zebrafish optic nerve and differentiation of hippocampal and N2a neurons. J Neurosci 2009, 29:6607-6615.
22. Wang C.Y., Shui H.A., Chang T.C. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer 2010, 126:578-582.
23. Xia Z., Tan M.M., Wong W.W., Dimitroulakos J., Minden M.D., Penn L.Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001, 15:1398-1407.
24. Chan K.K., Oza A.M., Siu L.L. The statins as anticancer agents. Clin Cancer Res 2003, 9:10-19.
25. Goplen D., Wang J., Enger P.O., Tysnes B.B., Terzis A.J., Laerum O.D., et al. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res 2006, 66:9895-9902.
26. Lexander H., Palmberg C., Auer G., Hellstrom M., Franzen B., Jornvall H., et al. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005, 27:263-272.
27. Pemberton T.J., Kay J.E. The cyclophilin repertoire of the fission yeast Schizosaccharomyces pombe. Yeast 2005, 22:927-945.
28. Li M., Zhai Q., Bharadwaj U., Wang H., Li F., Fisher W.E., et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006, 106:2284-2294.
29. Snell K. Enzymes of serine metabolism in normal and neoplastic rat tissues. Biochim Biophys Acta 1985, 843:276-281.
30. Nelson B.D., Kabir F. Adenylate kinase is a source of ATP for tumor mitochondrial hexokinase. Biochim Biophys Acta 1985, 841:195-200.
31. Prohl C., Pelzer W., Diekert K., Kmita H., Bedekovics T., Kispal G., et al. The yeast mitochondrial carrier Leu5p and its human homologue Graves' disease protein are required for accumulation of coenzyme A in the matrix. Mol Cell Biol 2001, 21:1089-1097.
32. Yeh C.S., Wang J.Y., Cheng T.L., Juan C.H., Wu C.H., Lin S.R. Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysis. Cancer Lett 2006, 233:297-308.
33. Martens J.W., Nimmrich I., Koenig T., Look M.P., Harbeck N., Model F., et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 2005, 65:4101-4117.
34. Ojala P., Sundstrom J., Gronroos J.M., Virtanen E., Talvinen K., Nevalainen T.J. mRNA differential display of gene expression in colonic carcinoma. Electrophoresis 2002, 23:1667-1676.
35. Hall M., Mickey D.D., Wenger A.S., Silverman L.M. Adenylate kinase: an oncodevelopmental marker in an animal model for human prostatic cancer. Clin Chem 1985, 31:1689-1691.
36. Battaini F., Pascale A. Protein kinase C signal transduction regulation in physiological and pathological aging. Ann N Y Acad Sci 2005, 1057:177-192.
37. Koike K., Fujii T., Nakamura A.M., Yokoyama G., Yamana H., Kuwano M., et al. Activation of protein kinase C delta induces growth arrest in NPA thyroid cancer cells through extracellular signal-regulated kinase mitogen-activated protein kinase. Thyroid 2006, 16:333-341.
38. Lehnigk U., Zimmermann U., Woenckhaus C., Giebel J. Localization of annexins I, II, IV and VII in whole prostate sections from radical prostatectomy patients. Histol Histopathol 2005, 20:673-680.
39. Schwartz-Albiez R., Koretz K., Moller P., Wirl G. Differential expression of annexins I and II in normal and malignant human mammary epithelial cells. Differentiation 1993, 52:229-237.
40. Wang W., Xu J., Kirsch T. Annexin V and terminal differentiation of growth plate chondrocytes. Exp Cell Res 2005, 305:156-165.
41. Igbavboa U., Eckert G.P., Malo T.M., Studniski A.E., Johnson L.N., Yamamoto N., et al. Murine synaptosomal lipid raft protein and lipid composition are altered by expression of human apoE 3 and 4 and by increasing age. J Neurol Sci 2005, 229-230:225-232.
42. Fortin D.L., Troyer M.D., Nakamura K., Kubo S., Anthony M.D., Edwards R.H. Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci 2004, 24:6715-6723.
43. Jeon J.H., Kim S.K., Kim H.J., Chang J., Ahn C.M., Chang Y.S. Lipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complex. Lung Cancer 2010, 69:165-171.